Incanthera Plc · AQUIS:INC
Incanthera — Investor Presentation (May 2024)
14 slides from Incanthera's investor presentation, May 2024
Slide 1: From Biotech Breakthrough to Partnership and Profitability
From Biotech Breakthrough to Partnership and Profitability Incanthera plc's Game-Changing Launch with the World’s Largest Health and Beauty Retailer Proactive Investor Presentation: May 2024
Slide 2: Disclaimer
Innovative Products for Dermatology and Oncology Disclaimer The information contained in these slides and any accompanying verbal presentation, any question and answer session and any document or material distributed at or in connection with the verbal presentation (together, the “Presentation”) hav
Slide 3: Introduction to Incanthera
Innovative Products for Dermatology and Oncology Introduction to Incanthera • Incanthera is a specialist company dedicated to innovative technologies in dermatology and oncology. • Established as a spin out from the Institute of Cancer Therapeutics, University of Bradford (UoB) in 2010, Incanthera h
Slide 4: Innovation into a Rapidly Growing Market
Innovative Products for Dermatology and Oncology Innovation into a Rapidly Growing Market • Incanthera has drawn on its recent IP, formulation expertise and delivery technologies to develop Skin + CELL: a unique skincare range: • Skin+CELL is a revolutionary (biotech) skincare range that leverages t
Slide 5: Commercial Deal Summary (RNS December 2023)
Innovative Products for Dermatology and Oncology Commercial Deal Summary (RNS December 2023) Incanthera’s existing, unique and proven skin delivery technology has been developed into a new range of luxury skincare products, following commercial discussions with Marionnaud, (part of A.S. Watson*). Th
Slide 6: Commercial Update (RNS March 2024)
Innovative Products for Dermatology and Oncology Commercial Update (RNS March 2024) • First order to generate revenue of c. £2m • First order doubled in size to 50,000 units: *One unit being one bottle of product i.e. face cream, hand cream etc. o Strong demand from customers anticipated by Marionna
Slide 7: Cellular Nourishment
Innovative Products for Dermatology and Oncology CELLULAR NOURISHMENT Our complementary range of products combine unique scientific formulations with our leading-edge delivery technology to effect cellular rejuvenation and repair. The result is a prestige cosmetic product range for ultimate nourishm
Slide 8: Cellular Repair
Innovative Products for Dermatology and Oncology CELLULAR REPAIR Bioactive Vit B3, also known as Niacinamide, is well established as playing a key role in energising the living cells of the skin, important in maintaining a natural healthy state and helping protect against adverse environmental chall
Slide 9: Incanthera's Transformational Revenue Opportunity
Innovative Products for Dermatology and Oncology Incanthera’s Transformational Revenue Opportunity • Confidence expressed by Marionnaud for Skin + CELL’s strong science-based skincare offer in their European network, and the strong relationship between the companies • Based on discussions with Mario
Slide 10: Analyst Research - Stanford Capital Partners: March 2024
Innovative Products for Dermatology and Oncology Analyst Research - Stanford Capital Partners: March 2024 EUROPEAN ROLL OUT 1200 STORES 2025 2026 2027 2028 2029 2030 Av Unit Price (£) 34 35 35 35 35 35 Units sold 300,000 936,000 1,060,800 1,185,600 1,248,000 1,310,400 Revenue £m 10.1 32.8 37.1 41.5
Slide 11: Share price – supported by IR and commercial newsflow
Innovative Products for Dermatology and Oncology Share price – supported by IR and commercial newsflow • Wealth of opportunity for commercial and financial RNS to support retail buying and share price • Proactive relationships with market makers and Aquis Exchange on IR/PR initiatives • Open communi
Slide 12: Incanthera plc Shareholder Analysis
Innovative Products for Dermatology and Oncology Incanthera plc Shareholder Analysis Institutional, 19.81% Retail, 31.81%, University, 11.16% Management, 7.36% Venture capital, 17.63% Corporate, 12.23% Shareholder Percentage of shares Number of shares Institutional 19.81% 19,667,353 University 11.16
Slide 13: Investment Summary
Innovative Products for Dermatology and Oncology Investment Summary Commercial revenues from launch and subsequent roll out of deal with world’s largest health and beauty retailer 2024 will produce multi-million £ revenues, profitability and cash generation Potential for significant uplift in Compan
Slide 14: The Incanthera plc Management Team
Innovative Products for Dermatology and Oncology The Incanthera plc Management Team Suzanne Brocks Tim McCarthy Simon Ward Caroline Murray Laura Brogden Shareholders, Market Specialist, Dermatology Financial Control City & Company Corporate & City Technology & and NED (Board) & Governance Head of Ch